The trial is designed to assess DrugSorb-ATR’s potential to lower perioperative bleeding in patients undergoing cardiothoracic surgery on ticagrelor. Credit: Sasin Tipchai from Pixabay.

CytoSorbents has concluded the patient recruitment in its pivotal study designed to assess DrugSorb-ATR’s potential to lower perioperative bleeding in patients undergoing cardiothoracic surgery on AstraZeneca’s blood thinner ticagrelor (Brilinta).

The Safe and Timely Antithrombotic Removal – Ticagrelor (STAR-T) controlled and randomised trial aims to demonstrate DrugSorb-ATR’s capability in the removal of ticagrelor antithrombotic agent to reduce perioperative bleeding.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Several major cardiothoracic surgery centres in North America are carrying out the trial.

It is intended to support marketing approval from Health Canada and the US Food and Drug Administration (FDA) for DrugSorb-ATR in this application.

DrugSorb-ATR’s objective is to facilitate timely access to necessary surgeries for patients while reducing the risk of bleeding by actively eliminating the drug at the time of surgery.

CytoSorbents has secured breakthrough device designation from the US FDA for DrugSorb-ATR for this indication.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Brilinta is administered as a component of dual-antiplatelet therapy for patients who are suspected of having a heart attack.

CytoSorbents chief medical officer Dr Efthymios Deliargyris said: “With this major milestone achieved, our attention now turns to completion of data collection and study closeout activities ahead of the final results.

“With our clinical operations capabilities now fully in place we look forward to executing the next round of trials, including STAR-D, investigating the expansion of antithrombotic drug removal to additional agents and hospital-wide applications beyond cardiac surgery.”

CytoSorb, which is the company’s lead product, received approval in the European Union and is supplied in 75 countries across the world.